Images List Premium Download Classic

Infectious

Infectious-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer
University Of Florida Research Foundation, Incorporated
August 09, 2018 - N°20180223312

Disclosed are next-generation multi-mutated capsid protein-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions ...
Combination therapies comprising antibody molecules to pd-1
President And Fellows Of Harvard College
August 09, 2018 - N°20180222982

Combination therapies comprising antibody molecules that specifically bind to pd-1 disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders..
Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
Counterpoint Biomedica Llc
August 09, 2018 - N°20180222959

Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing fusion polypeptides. These fusion polypeptides contain two or more domains: (i) aptamer sequences that bind to exposed collagenous (xc-) proteins present in pathological areas, including cancerous and viral lesions, (ii) immunomodulators, such as cytokines, and optionally (iii) at least one linker joining the two ...
Infectious Patent Pack
Download 268+ patent application PDFs
Infectious Patent Applications
Download 268+ Infectious-related PDFs
For professional research & prior art discovery
inventor
  • 268+ full patent PDF documents of Infectious-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in ...
Universite De Nantes
August 09, 2018 - N°20180221469

The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory c protein has been knocked out (mv-deltac). It concerns in particular the use of said genetically modified infectious mv-deltac in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or ...
Antimicrobial fusion peptides
La Biomed
August 09, 2018 - N°20180221439

Antimicrobial peptides, compositions and methods are described that are useful for treating infectious diseases, including those caused by drug resistant gram-negative bacteria (e.g., pseudomonas and acinetobacter) and parasite-caused diseases such as malaria. The peptides include a modular kinocidin gamma-core connected directly, or through a short spacer, to a kinocidin c-terminal alpha-helix..
Reagents and methods for detecting infectious diseases
Ionica Sciences
August 02, 2018 - N°20180217068

Provided herein are surface enhanced raman scattering (sers)-active reagents and methods for detecting one or more analyte in a sample. Said sers-active reagents are adaptable, sensitive, and easy-to-use in the diagnosis of infectious diseases in a patient, or the detection of toxins, bacteria, viruses, pathogens, hormones, cytokines, antigens, antibodies or illicit drugs in a biological sample.
Infectious Patent Pack
Download 268+ patent application PDFs
Infectious Patent Applications
Download 268+ Infectious-related PDFs
For professional research & prior art discovery
inventor
  • 268+ full patent PDF documents of Infectious-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
Beigene, Ltd.
August 02, 2018 - N°20180215825

Provided are antibodies that specifically bind to programmed death-1 (pd1, pdcd-1, or cd279) ligand (pd-l1) and inhibit pd-l1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by pd-l1-mediated ...
Treating cancer with viral nucleic acid
Mayo Foundation For Medical Education And Research
August 02, 2018 - N°20180215794

This document provides methods and materials related to the use of nucleic acid coding for viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, methods for making engineered viral nucleic acid, methods for identifying infectious nucleic acid for treating cancer, methods and ...
1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
Chong Kun Dang Pharmaceutical Corp.
August 02, 2018 - N°20180215743

The present invention relates to novel compounds having histone deacetylase 6 (hdac6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according ...
Replication-competent vesicular stomatitis viruses
Mayo Foundation For Medical Education And Research
August 02, 2018 - N°20180214497

This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided..
New effective aminoglycoside antibiotic for multidrug-resistant bacteria
Meiji Seika Pharma Co., Ltd.
August 02, 2018 - N°20180214470

A compound represented by the following general formula (i) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (i) has an antibacterial activity against both gram-positive and ...
Compounds for treatment or prevention of disorders of the nervous system and symptoms and manifestations ...
August 02, 2018 - N°20180214395

The present invention relates to a method of treating or preventing cellular dysfunction and death caused by genetic, degenerative, toxic, traumatic, ischemic, infectious, neoplastic and inflammatory diseases and aging—and their neurological symptoms and manifestations, which includes administering d-methadone, beta-d-methadol, alpha-l-methadol, beta-l-methadol, alpha-d-methadol, acetylmethadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, beta-d-acetylmethadol, beta-l-acetylmethadol, d-alpha-normethadol, l-alpha normethadol, noracetylmethadol, dinoracetylmethadol, methadol, normethadol, dinormethadol, eddp, emdp, d-isomethadone, ...
Dimethyl sulfoxide (dmso) or dmso and methylsulfonylmethane (msm) formulations to treat infectious diseases
Abela Pharmaceuticals, Inc.
August 02, 2018 - N°20180214373

Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (dmso) alone or in combination with methylsulfonylmethane (msm), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis..
Infectious Patent Pack
Download 268+ patent application PDFs
Infectious Patent Applications
Download 268+ Infectious-related PDFs
For professional research & prior art discovery
inventor
  • 268+ full patent PDF documents of Infectious-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-pd-l1 antibodies and uses thereof
I-mab
July 26, 2018 - N°20180208659

Provided are anti-pd-l1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin c domain of the pd-l1 protein.
Anti-semaphorin 3a antibody and treatment of alzheimer's disease and inflammatory immune diseases using same
Chiome Bioscience Inc.
July 26, 2018 - N°20180208644

The present invention mainly addresses the problem of providing an antibody against semaphorin 3a protein, said antibody enabling effective prevention and/or treatment of a disease, in which sema 3a protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. Or disseminated intravascular coagulation syndrome.
Combination therapies comprising antibody molecules to tim-3
Children's Medical Center Corporation
July 26, 2018 - N°20180207273

Combination therapies comprising antibody molecules that specifically bind to tim-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders..
Pharmaceutical compositions comprising danirixin for treating infectious diseases
Glaxosmithkline Intellectual Property (no. 2) Limited
July 26, 2018 - N°20180207145

Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease.. .
Method for rapid generation of an attenuated rna virus
Inserm
July 19, 2018 - N°20180201908

The present invention harnesses the power of mutagenesis to produce an attenuated rna virus in a very short period, i.e. As soon as the complete sequence of the target virus is known and an infectious genome can be produced..
Optimized hcv full-length infectious cell culture systems and applications thereof
Københavns Universitet
July 19, 2018 - N°20180201905

The present invention relates to nucleic acid sequences that encode hepatitis c viruses (hcv) that are useful in the fundamental research of hcv as well as in the search of a vaccine against hcv. In particular the present invention relates to nucleic acid sequences that comprises hcvs which are capable of expressing said virus when transfected into cells and are ...
Processing of a modified foot-and-mouth disease virus p1 polypeptide by an alternative protease
The Government Of The United States Of America, As Represented By The Secretary Of Homeland Security
July 19, 2018 - N°20180200359

Polynucleotide constructs that express an engineered foot-and-mouth disease (fmdv) p1 precursor protein and a non-fmdv tev protease and methods for safe and efficient recombinant production of fmdv antigens and immunogens. Recombinant production of fmdv antigens avoids the need to culture highly-infectious fmdv, while conventional culture methods for producing fmdv antigens rely on the native fmdv 3c protease which exerts toxic ...
Pd-1 peptide inhibitors
Leidos, Inc.
July 19, 2018 - N°20180200328

This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (pd-1). These peptides block the interaction of pd-1 with its ligand pd-l1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating ...
Loading